Announcement • May 28
LBX Pharmacy Chain Joint Stock Company, Annual General Meeting, Jun 18, 2026 LBX Pharmacy Chain Joint Stock Company, Annual General Meeting, Jun 18, 2026, at 15:30 China Standard Time. Location: 15F, No. 808, Qingzhuhu Road, Kaifu District, Changsha, Hunan China Board Change • May 20
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. 3 independent directors (7 non-independent directors). Independent Director Ziqi Xie was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Announcement • Mar 30
LBX Pharmacy Chain Joint Stock Company to Report Q1, 2026 Results on Apr 23, 2026 LBX Pharmacy Chain Joint Stock Company announced that they will report Q1, 2026 results on Apr 23, 2026 Announcement • Dec 26
LBX Pharmacy Chain Joint Stock Company to Report Fiscal Year 2025 Results on Apr 23, 2026 LBX Pharmacy Chain Joint Stock Company announced that they will report fiscal year 2025 results on Apr 23, 2026 Announcement • Sep 30
LBX Pharmacy Chain Joint Stock Company to Report Q3, 2025 Results on Oct 29, 2025 LBX Pharmacy Chain Joint Stock Company announced that they will report Q3, 2025 results on Oct 29, 2025 Announcement • Jun 30
LBX Pharmacy Chain Joint Stock Company to Report First Half, 2025 Results on Aug 30, 2025 LBX Pharmacy Chain Joint Stock Company announced that they will report first half, 2025 results on Aug 30, 2025 Announcement • Jun 09
LBX Pharmacy Chain Joint Stock Company, Annual General Meeting, Jun 30, 2025 LBX Pharmacy Chain Joint Stock Company, Annual General Meeting, Jun 30, 2025, at 15:30 China Standard Time. Location: 15F, No. 808, Qingzhuhu Road, Kaifu District, Changsha, Hunan China Announcement • Mar 28
LBX Pharmacy Chain Joint Stock Company to Report Q1, 2025 Results on Apr 30, 2025 LBX Pharmacy Chain Joint Stock Company announced that they will report Q1, 2025 results on Apr 30, 2025 Announcement • Dec 27
LBX Pharmacy Chain Joint Stock Company to Report Fiscal Year 2024 Results on Apr 30, 2025 LBX Pharmacy Chain Joint Stock Company announced that they will report fiscal year 2024 results on Apr 30, 2025 Valuation Update With 7 Day Price Move • Nov 05
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥19.25, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 13x in the Consumer Retailing industry in China. Total loss to shareholders of 23% over the past three years. Reported Earnings • Oct 30
Third quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.26 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.17 (down from CN¥0.26 in 3Q 2023). Revenue: CN¥5.29b (up 1.2% from 3Q 2023). Net income: CN¥127.4m (down 37% from 3Q 2023). Profit margin: 2.4% (down from 3.9% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Upcoming Dividend • Oct 03
Upcoming dividend of CN¥0.33 per share Eligible shareholders must have bought the stock before 10 October 2024. Payment date: 10 October 2024. Payout ratio is a comfortable 70% and this is well supported by cash flows. Trailing yield: 2.9%. Within top quartile of Chinese dividend payers (2.2%). Higher than average of industry peers (1.9%). Announcement • Sep 30
LBX Pharmacy Chain Joint Stock Company to Report Q3, 2024 Results on Oct 30, 2024 LBX Pharmacy Chain Joint Stock Company announced that they will report Q3, 2024 results on Oct 30, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CN¥15.80, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 12x in the Consumer Retailing industry in China. Total loss to shareholders of 40% over the past three years. Valuation Update With 7 Day Price Move • Sep 04
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to CN¥14.81, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 11x in the Consumer Retailing industry in China. Total loss to shareholders of 46% over the past three years. Buy Or Sell Opportunity • Sep 02
Now 24% undervalued after recent price drop Over the last 90 days, the stock has fallen 53% to CN¥12.24. The fair value is estimated to be CN¥16.07, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 9.8%. For the next 3 years, revenue is forecast to grow by 15% per annum. Earnings are also forecast to grow by 17% per annum over the same time period. Announcement • Jun 28
LBX Pharmacy Chain Joint Stock Company to Report First Half, 2024 Results on Aug 30, 2024 LBX Pharmacy Chain Joint Stock Company announced that they will report first half, 2024 results on Aug 30, 2024 Valuation Update With 7 Day Price Move • Jun 28
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥18.36, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 17x in the Consumer Retailing industry in China. Total loss to shareholders of 37% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥16.59 per share. Declared Dividend • Jun 23
Dividend increased to CN¥0.66 Dividend of CN¥0.66 is 32% higher than last year. Ex-date: 27th June 2024 Payment date: 27th June 2024 Dividend yield will be 2.3%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (40% earnings payout ratio) and cash flows (22% cash payout ratio). The dividend has increased by an average of 19% per year over the past 8 years. However, payments have been volatile during that time. EPS is expected to grow by 65% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • May 24
LBX Pharmacy Chain Joint Stock Company, Annual General Meeting, Jun 13, 2024 LBX Pharmacy Chain Joint Stock Company, Annual General Meeting, Jun 13, 2024, at 14:30 China Standard Time. Location: 15F, No. 808, Qingzhuhu Road, Kaifu District, Changsha, Hunan China Reported Earnings • Apr 30
Full year 2023 earnings released: EPS: CN¥1.59 (vs CN¥1.36 in FY 2022) Full year 2023 results: EPS: CN¥1.59 (up from CN¥1.36 in FY 2022). Revenue: CN¥22.4b (up 11% from FY 2022). Net income: CN¥929.0m (up 18% from FY 2022). Profit margin: 4.1% (up from 3.9% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Announcement • Mar 29
LBX Pharmacy Chain Joint Stock Company to Report Q1, 2024 Results on Apr 30, 2024 LBX Pharmacy Chain Joint Stock Company announced that they will report Q1, 2024 results on Apr 30, 2024 Valuation Update With 7 Day Price Move • Feb 07
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥31.93, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 18x in the Consumer Retailing industry in China. Total loss to shareholders of 45% over the past three years. Announcement • Dec 29
LBX Pharmacy Chain Joint Stock Company to Report Fiscal Year 2023 Results on Apr 30, 2024 LBX Pharmacy Chain Joint Stock Company announced that they will report fiscal year 2023 results on Apr 30, 2024 Reported Earnings • Nov 01
Third quarter 2023 earnings released: EPS: CN¥0.34 (vs CN¥0.26 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.34 (up from CN¥0.26 in 3Q 2022). Revenue: CN¥5.23b (up 9.3% from 3Q 2022). Net income: CN¥203.3m (up 33% from 3Q 2022). Profit margin: 3.9% (up from 3.2% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. Reported Earnings • Sep 05
Second quarter 2023 earnings released: EPS: CN¥0.38 (vs CN¥0.38 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.38. Revenue: CN¥5.37b (up 11% from 2Q 2022). Net income: CN¥221.9m (up 3.4% from 2Q 2022). Profit margin: 4.1% (down from 4.4% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Consumer Retailing industry in China. Reported Earnings • Apr 29
Full year 2022 earnings released: EPS: CN¥1.36 (vs CN¥1.26 in FY 2021) Full year 2022 results: EPS: CN¥1.36 (up from CN¥1.26 in FY 2021). Revenue: CN¥20.2b (up 28% from FY 2021). Net income: CN¥785.0m (up 17% from FY 2021). Profit margin: 3.9% (down from 4.3% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Buying Opportunity • Apr 19
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 16%. The fair value is estimated to be CN¥43.87, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 10%. For the next 3 years, revenue is forecast to grow by 17% per annum. Earnings is also forecast to grow by 18% per annum over the same time period. Buying Opportunity • Apr 03
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 19%. The fair value is estimated to be CN¥43.77, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 10%. Revenue is forecast to grow by 44% in 2 years. Earnings is forecast to grow by 52% in the next 2 years. Buying Opportunity • Dec 22
Now 22% undervalued Over the last 90 days, the stock is up 27%. The fair value is estimated to be CN¥48.28, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 10%. Revenue is forecast to grow by 43% in 2 years. Earnings is forecast to grow by 51% in the next 2 years. Valuation Update With 7 Day Price Move • Nov 18
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥42.73, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 25x in the Consumer Retailing industry in China. Total returns to shareholders of 14% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥56.79 per share. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Lianfeng Wu was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 30
Third quarter 2022 earnings released: EPS: CN¥0.26 (vs CN¥0.24 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.26 (up from CN¥0.24 in 3Q 2021). Revenue: CN¥4.79b (up 25% from 3Q 2021). Net income: CN¥153.1m (up 21% from 3Q 2021). Profit margin: 3.2% (down from 3.3% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 30
First quarter 2022 earnings released: EPS: CN¥0.53 (vs CN¥0.56 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.53. Revenue: CN¥4.14b (up 14% from 1Q 2021). Net income: CN¥241.8m (up 6.3% from 1Q 2021). Profit margin: 5.8% (down from 6.3% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 22%, compared to a 16% growth forecast for the industry in China. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 6 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Yang Haiyu was the last independent director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Aug 19
Second quarter 2021 earnings released: EPS CN¥0.43 (vs CN¥0.35 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥3.82b (up 12% from 2Q 2020). Net income: CN¥178.3m (up 28% from 2Q 2020). Profit margin: 4.7% (up from 4.1% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Reported Earnings • Apr 29
First quarter 2021 earnings released: EPS CN¥0.56 (vs CN¥0.49 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥3.64b (up 11% from 1Q 2020). Net income: CN¥227.5m (up 16% from 1Q 2020). Profit margin: 6.3% (up from 6.0% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Is New 90 Day High Low • Mar 13
New 90-day low: CN¥61.56 The company is down 7.0% from its price of CN¥65.89 on 11 December 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥48.82 per share. Is New 90 Day High Low • Jan 13
New 90-day high: CN¥81.64 The company is up 3.0% from its price of CN¥79.48 on 16 October 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥63.07 per share. Valuation Update With 7 Day Price Move • Jan 12
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥78.46, the stock is trading at a trailing P/E ratio of 53.3x, up from the previous P/E ratio of 46x. This compares to an average P/E of 32x in the Consumer Retailing industry in China. Total returns to shareholders over the past three years are 84%. Is New 90 Day High Low • Dec 28
New 90-day low: CN¥63.60 The company is down 23% from its price of CN¥82.98 on 30 September 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥63.07 per share. Is New 90 Day High Low • Dec 11
New 90-day low: CN¥65.89 The company is down 19% from its price of CN¥81.54 on 11 September 2020. The Chinese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥63.07 per share. Is New 90 Day High Low • Nov 17
New 90-day low: CN¥67.21 The company is down 11% from its price of CN¥75.86 on 19 August 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥53.67 per share. Reported Earnings • Oct 30
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥601.8m, up 19% from the prior year. Total revenue was CN¥13.4b over the last 12 months, up 21% from the prior year.